The limited efficacy of benznidazole (Bz) indicated by failures of current Phase II clinical
trials emphasizes the urgent need to identify new drugs with improved safety and efficacy for …

Chagas disease (CD) still represents a serious public health problem in Latin America, even
after more than 100 years of its discovery. Clinical treatments (nifurtimox and benznidazole) …

Chagas disease, caused by Trypanosoma cruzi, is a widespread infection in Latin America.
Currently, only 2 partially effective and highly toxic drugs, ie, benznidazole and nifurtimox …

In the search for new therapeutic alternatives for Chagas disease, a series of six aryloxy-
naphthoquinone derivatives were synthesized and evaluated in vitro against Trypanosoma …

In the present study, the potential activity of two 5-nitroindazole derivatives previously
proposed as suitable antichagasic prototypes was further evaluated on diverse …

The growth inhibitory effect on Trypanosoma cruzi epimastigotes and the unspecific
cytotoxicity over NCTC-929 fibroblasts of two series of previously synthesized 2, 4-diaryl-1 …

To develop novel chemotherapeutic alternatives for the treatment of Chagas disease, in this
study, a set of new amino naphthoquinone derivatives were synthesised and evaluated in …

The development of new drugs against Chagas disease is a priority since the currently
available medicines have toxic effects, partial efficacy and are targeted against the acute …

Chagas disease is one of the most important endemic diseases in Latin America, caused by
Trypanosoma cruzi. The drugs used for the treatment of this disease, nifurtimox and …

Background: Chagas disease affects about 7 million people worldwide. Only two drugs are
currently available for the treatment for this parasite disease, namely, benznidazol (Bzn) and …